The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.
Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and ... again be in focus when Novo reports results for its diabetes drug Ozempic and ...
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.